Literature DB >> 28408007

Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.

Nathan S McClure1, Fatima Al Sayah1, Feng Xie2, Nan Luo3, Jeffrey A Johnson4.   

Abstract

BACKGROUND: The five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) is a preference-based measure of health-related quality of life (HRQOL), which yields an index score anchored at 0 (dead) and 1 (full health). We lack evidence on estimates for the minimally important difference (MID) of the EQ-5D-5L that will help in interpreting differences or changes in HRQOL measured by this scale score.
OBJECTIVES: To estimate the MID of the EQ-5D-5L index score for available scoring algorithms including algorithms from Canada, China, Spain, Japan, England, and Uruguay.
METHODS: A simulation-based approach based on instrument-defined single-level transitions was used to estimate the MID values of the EQ-5D-5L for each country-specific scoring algorithm.
RESULTS: The simulation-based instrument-defined MID estimates (mean ± SD) for each country-specific scoring algorithm were as follows: Canada, 0.056 ± 0.011; China, 0.069 ± 0.007; Spain, 0.061 ± 0.008; Japan, 0.048 ± 0.004; England, 0.063 ± 0.013; and Uruguay, 0.063 ± 0.019. Differences in MID estimates reflect differences in population preferences, in valuation techniques used, as well as in modeling strategies. After excluding the maximum-valued scoring parameters, the MID estimates (mean ± SD) were as follows: Canada, 0.037 ± 0.001; China, 0.058 ± 0.005; Spain, 0.045 ± 0.009; Japan, 0.044 ± 0.004; England, 0.037 ± 0.008; and Uruguay, 0.040 ± 0.010.
CONCLUSIONS: Simulation-based estimates of the MID of the EQ-5D-5L index score were generally between 0.037 and 0.069, which are similar to the MID estimates of other preference-based HRQOL measures.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Keywords:  EQ-5D-5L; health state preference; health state utility; minimally important difference

Mesh:

Year:  2017        PMID: 28408007     DOI: 10.1016/j.jval.2016.11.015

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  61 in total

1.  Evaluation of uptake and effect on patient-reported outcomes of a clinician and patient co-led chronic musculoskeletal pain self-management programme provided by the UK National Health Service.

Authors:  Joanna K Anderson; Louise M Wallace
Journal:  Br J Pain       Date:  2017-09-26

2.  The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.

Authors:  E Haydn Walters; Andrew J Palmer; Ingrid A Cox; Barbara de Graaff; Hasnat Ahmed; Julie Campbell; Petr Otahal; Tamera J Corte; Ian Glaspole; Yuben Moodley; Nicole Goh; Sacha Macansh
Journal:  Qual Life Res       Date:  2021-05-17       Impact factor: 4.147

3.  Validity of the EQ-5D-5L and reference norms for the Spanish population.

Authors:  Gimena Hernandez; Olatz Garin; Yolanda Pardo; Gemma Vilagut; Àngels Pont; Mónica Suárez; Montse Neira; Luís Rajmil; Inigo Gorostiza; Yolanda Ramallo-Fariña; Juan Cabases; Jordi Alonso; Montse Ferrer
Journal:  Qual Life Res       Date:  2018-05-16       Impact factor: 4.147

4.  A randomized trial comparing health-related quality-of-life and utility measures between routine fine-needle aspiration cytology (FNAC) and surveillance alone in patients with thyroid incidentaloma measuring 1-2 cm.

Authors:  Carlos K H Wong; Brian H H Lang
Journal:  Endocrine       Date:  2019-11-18       Impact factor: 3.633

5.  Discrepancies between proxy estimates and patient reported, health related, quality of life: minding the gap between patient and clinician perceptions in heart failure.

Authors:  Roslyn A Prichard; Fei-Li Zhao; Julee Mcdonagh; Stephen Goodall; Patricia M Davidson; Phillip J Newton; Ben Farr-Wharton; Christopher S Hayward
Journal:  Qual Life Res       Date:  2021-01-02       Impact factor: 4.147

6.  Use, cost-effectiveness, and end user perspectives of a home solar lighting intervention in rural Uganda: a mixed methods, randomized controlled trial.

Authors:  Radhika Sundararajan; Helen D'Couto; Joseph Mugerwa; Mellon Tayebwa; Nicholas Lam; Eli Wallach; Matthew Wiens; Matthew Ponticiello; Debbi Stanistreet; Alexander C Tsai; Jose Vallarino; Joseph G Allen; Daniel Muyanja; Mark G Shrime; Edwin Nuwagira; Peggy S Lai
Journal:  Environ Res Lett       Date:  2021-12-22       Impact factor: 6.793

7.  Health-related quality of life and mental well-being of healthy and diseased persons in 8 countries: Does stringency of government response against early COVID-19 matter?

Authors:  Di Long; Juanita A Haagsma; Mathieu F Janssen; John N Yfantopoulos; Erica I Lubetkin; Gouke J Bonsel
Journal:  SSM Popul Health       Date:  2021-09-01

8.  Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).

Authors:  Philippe Moreau; Shaji Kumar; Ralph Boccia; Shinsuke Iida; Hartmut Goldschmidt; Kim Cocks; Andrew Trigg; Anita Zahlten-Kumeli; Emre Yucel; Sumeet S Panjabi; Meletios Dimopoulos
Journal:  Leukemia       Date:  2019-05-15       Impact factor: 11.528

9.  Quality of Life in Palliative Care.

Authors:  Mellar P Davis; David Hui
Journal:  Expert Rev Qual Life Cancer Care       Date:  2017-11-08

10.  Utility Index and Patient-Reported Outcome Measures in Glaucomatous Patients Comparing with Normal Participants.

Authors:  Kulawan Rojananuangnit; Nuttawan Sudjinda
Journal:  Clin Ophthalmol       Date:  2021-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.